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Abstract
Rationale:Mesenchymal stem cells (MSC) play a crucial role in both the maintenance of pulmonary integrity and the pathogenesis
of lung disease. Lung involvement has been reported in patients with the filamin A (FLNA) gene mutation. Considering FLNA’s role in
the intrinsic mechanical properties of MSC, we characterized MSCs isolated from FLNA-defective lung tissue, in order to define their
pathogenetic role in pulmonary damage.
Patient concerns: A male infant developed significant lung disease resulting in emphysematous lesions and perivascular and
interstitial fibrosis. He also exhibited general muscular hypotonia, bilateral inguinal hernia, and deformities of the lower limbs (pes
tortus congenitalis and hip dysplasia). Following lobar resection, chronic respiratory failure occurred.
Diagnosis:Genetic testing was performed during the course of his clinical care and revealed a new pathogenic variant of the FLNA
gene c.7391_7403del; (p.Val2464AlafsTer5). Brain magnetic resonance imaging revealed periventricular nodular heterotopia.
Interventions and outcomes: Surgical thoracoscopic lung biopsy was performed in order to obtain additional data on the
pathological pulmonary features. A small portion of the pulmonary tissue was used for MSC expansion. Morphology,
immunophenotype, differentiation capacity, and proliferative growth were evaluated. Bone marrow-derived mesenchymal stem cells
(BM-MSC) were employed as a control. MSCs presented the typical MSC morphology and phenotype while exhibiting higher
proliferative capacity (P<.001) and lower migration potential (P=.02) compared to control BM-MSC.
Lessons: The genetic profile and altered features of the MSCs isolated from FLNA-related pediatric lung tissue could be directly
related to defects in cell migration during embryonic lung development and pulmonary damage described in FLNA-defective patients.
Abbreviations: BM-MSC = bone marrow-derived mesenchymal stem cells, cPD = cumulative population doubling, FLNA =
filamin A, MSC = mesenchymal stem cells, SDF = stromal cell-derived factor.
Keywords: children, filamin A, lung, mesenchymal stem cells, tissue
1. Introduction
Filamins are cytoskeletal proteins that organize actin filaments
into networks and link these networks to cell membranes.
Filamin A (FLNA) is the most abundant and widely-expressed
protein among the 3 filamin isoforms. As a mediator of
cytoskeleton reorganization, it regulates actin filament disassem-
bly at the leading edge of motile cells and directs these filaments to
the filopodia, lamellipodia, stress fibers and focal contacts. It is
ubiquitously distributed, and null mutations have strong
consequences on embryonic development in humans, with organ
defects which suggest deficiencies in cell migration.[1]
Recently lung involvement has been reported in patients with
the FLNA gene mutation.[2–9] The specific role of FLNA in the
development of lung disease is still not fully understood. Many
lung diseases are driven by the maladaptive proliferation of
mesenchymal, epithelial, and endothelial cells, which results in
dysfunctional lung remodeling.[10]
Recent studies indicate that lung mesenchymal stem cells
(MSCs) may contribute to lung injury and repair and to
pulmonary disease progression.[11] Considering FLNA’s role in
the intrinsic mechanical properties of MSC, including cell
adhesion and migration, in this brief report, we characterized
Editor: N/A.
VC and MAAs contributed equally to this work
The authors did not receive any funding from public, commercial or non-profit
agencies to conduct this research.
The authors have no conflict of interests to declare.
a Pediatric Unit, Department of Internal Medicine University of Pavia and
Fondazione IRCCS Policlinico San Matteo, b Immunology and Transplantation
Laboratory, Cell Factory, Pediatric Hematology Oncology Unit, Department of
Maternal and Children’s Health, Fondazione IRCCS Policlinico S, Matteo, Pavia,
c Laboratory of Medical Genetics, Ospedale Pediatrico Bambino Gesù, Rome,
dBiometry & Clinical Epidemiology, Scientific Direction, Fondazione IRCCS
Policlinico San Matteo, Pavia, e Pediatric Anesthesiology and Intensive Care Unit,
f Cystic Fibrosis and Respiratory Pediatric Center, g Pediatric Surgery Department,
Children’s Hospital, ARNAS Civico-Di Cristina-Benfratelli, Palermo, Italy.
∗
Correspondence: Gloria Pelizzo, Pediatric Surgery Department, Children’s
Hospital, Via dei Benedettini n.1, 90134 Palermo, Italy (e-mail:
gloriapelizzo@gmail.com).
Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc.
This is an open access article distributed under the terms of the Creative
Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is
permissible to download, share, remix, transform, and buildup the work provided
it is properly cited. The work cannot be used commercially without permission
from the journal.
Medicine (2018) 97:50(e13033)
Received: 13 July 2018 / Accepted: 8 October 2018
http://dx.doi.org/10.1097/MD.0000000000013033
Clinical Case Report Medicine®
OPEN
1
MSCs isolated from FLNA- defective pediatric lung tissue in
terms of morphology, phenotype, differentiation capacity,
proliferative growth, and gene signature. These data should be
useful in defining the role of MSCs in pulmonary damage
described in FLNA-defective patients.
2. Material and methods
2.1. Ethical approval
This study was approved by the ethics committee of The
Children’s Hospital G. Di Cristina, ARNAS Civico-Di Cristina-
Benfratelli, Palermo, Italy
2.2. Consent statement
After written informed consent was obtained from the parents, a
small portion of the pulmonary tissue destined for histological
analysis was used for MSC expansion.
Informed consent was obtained from the parents for the
publication of this study.
3. Methods
3.1. Isolation and culture
Isolation and expansion of MSCs from pulmonary tissue were
performed following standard bone marrow culture procedures,
as previously described.[12,13] The pulmonary sample, after
cutting into small pieces, was incubated in the presence of 1mg/
mL collagenase type II (Sigma Aldrich, Milan Italy) in a-MEM
(Gibco, Milan Italy) at 37°C, 5% CO2 for 30 minutes.
Collagenase activity was blocked by adding a-MEM (Gibco)
10% FBS (Euroclone, Milan Italy) and the cell suspension was
collected and plated in polystyrene culture flasks (Corning
Costar, Corning, NY) at a density of 160,000/cm2 in complete
culture medium: D-MEM (Gibco) 10% FBS (Euroclone),
gentamicin 50mg/mL, and penicillin 100U/mL.
Culturesweremaintained at 37°C,5%CO2, and themediumwas
replaced twice aweek.WhenMSCs reached≥80%confluence, they
were harvested with Trypsin EDTA (Lonza, Milan, Italy) and
replated for expansion at a density of 4000cells/cm2.
4. Characterization of ex-vivo expanded MSCs
4.1. Proliferative capacity
Proliferative capacity was defined as cumulative population
doubling (cPD) calculated following the formula PD= log (n. of
harvested cells/n. of seeded cells)/log. Bone marrow-derived
mesenchymal stem cells (BM-MSC) from healthy donors were
employed as a control.
4.2. Immune phenotype
Cell immunophenotyping was performed by flow-cytometry.
Fluorescein isothiocyanate (FITC)- or phycoerythrin (PE)-
conjugated monoclonal antibodies specific for CD73, CD34,
CD90, CD14, CD45, CD31, CD105, HLA-I and HLA-DR and
CXCR4 (Beckman Coulter, IL, Milan, Italy) were used.
Appropriate, isotype-matched, non-reactive fluorochrome-con-
jugated antibodies were employed as controls. Cell populations
were analyzed by direct immunofluorescence with a FACS
Navios flow-cytometer (BC).
4.3. Differentiation capacity
The differentiation capacity of MSCs was assessed by incubating
cells for at least 2 weeks at 37°C, 5% CO2 in differentiation
medium: aMEM (Euroclone), 10% FBS, 10–7M dexamethasone,
50mg/ml L-ascorbic acid and 5mM ß-glycerol phosphate (all
from Sigma-Aldrich). For adipogenic differentiation 100mg/mL
insulin, 50mM isobutyl methylxanthine, 0.5mM indomethacin
(Sigma-Aldrich), and 5mM b-glycerol phosphate were also
added. To detect osteogenic differentiation, cells were stained for
alkaline phosphatase (AP) activity using Fast Blue (Sigma-
Aldrich) and for calcium deposition with Alizarin Red (Sigma-
Aldrich). Adipogenic differentiation was assessed based on the
morphological appearance of fat droplets after staining with Oil
Red O (Sigma-Aldrich).
4.4. Senescence assay
Cells were maintained in culture until they reached senescence. In
order to reveal any change in morphology and/or proliferation
rate, MSCs were closely monitored during senescence for up to 8
to 12 weeks before interrupting the cultures. Senescence of MSCs
was assessed by staining with the b-galactosidase (SA-b-gal)
staining Kit (Cell Signaling Technology, Danvers, MA), accord-
ing to the manufacturer’s instructions and evaluated by direct-
light microscopy.
4.5. Migration assay
The cell migration assay was performed with the transwell
migration chamber system (Merck Millipore, Milan, Italy),
utilizing polycarbonate inserts with an 8 mm pore size, as
previously described.[14] Briefly, 5103cells/well were seeded in
the upper chambers of the 96-well plate. For each condition, the
lower chambers were filled with 150 mL of basal medium with or
without stromal cell-derived factor (SDF). The cells were left to
migrate for 16hours at 37° C and 5% CO2. At the end of the
incubation, the underside of the membranes was fixed with 4%
paraformaldehyde for 20 minutes. Cell nuclei were then stained
with Hoechst 33258 (Life Technologies, Monza, Italy). Finally,
the membranes were cut out and mounted onto glass slides with
ProLong Gold antifade reagent (Life Technologies, Monza,
Italy). Three replicates were evaluated for each condition. Images
were acquired using an Olympus BX51 microscope (Olympus,
Deutschland GmbH, Hamburg, Germany). The number of
migrated cells was blindly-counted analyzing 15 random fields of
the membranes per condition. Data were expressed as the means
of the number of migrated cells± standard error (SE).
The number of migrated FLNA-MSCs was compared to the
number of migrated BM-MSCs from healthy donors.
4.6. Genetic characterization
After obtaining informed consent for the genetic analyses,
hybridization target enrichment and parallel sequencing were
performed on genomic DNA extracted from pulmonaryMSCs of
the FLNA-defective patient. Sequences of the FLNA gene were
enriched by using a custom NimbleGen SeqCap EZ Choice kit
(Roche NimbleGen Inc., Madison, WI, USA) according to the
manufacturer’s protocol, and sequenced on the Illumina
NextSeq550 platform. The BaseSpace pipeline (Illumina,
https://basespace.illumina.com/) and the TGexTM software
(LifeMap Sciences) were used for the variant naming and
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annotating variants, respectively. Sequencing data were aligned
to the hg19 human reference genome.
4.7. Statistical analysis
Proliferative capacity of the patient’s MSCs was compared with
controls using the z-statistic, while the number of migrated cells
was compared between the patient and controls with the t test for
independent samples. Statistical significance was defined as a P
value<.05. Data analyses were performed with the STATA
statistical package (release 14.2, 2012, Stata Corporation,
College Station, TX).
4.8. Case report
A male infant was referred to our surgical department, with a
presumptive diagnosis of congenital lobar emphysema. He
developed significant lung disease resulting in emphysematous
lesions and perivascular and interstitial fibrosis. He also exhibited
general muscular hypotonia, bilateral inguinal hernia, and
deformities of the lower limbs (pes tortus congenitalis and hip
dysplasia). Following lobar resection, chronic respiratory failure
occurred, necessitating mechanical ventilation to assist the
patient’s breathing. The decision to perform a surgical thoraco-
scopic lung biopsy was made in order to obtain additional data
on the pathological pulmonary features for prognostic predic-
tions and therapeutic decisions.
Genetic testing was performed during the course of his clinical
care and revealed a new pathogenic variant of the FLNA gene
c.7391_7403del; (p.Val2464AlafsTer5). Brain magnetic reso-
nance imaging revealed periventricular nodular heterotopia.
A small portion (1cm 1cm) of the pulmonary tissue obtained
to lung biopsy was used for MSC expansion.
4.9. MSC expansion and characterization
Cells were isolated and expanded from pulmonary tissue of the
FLNA-defective patient using the same standard culture
conditions used for BM-MSC. The cells were plastic adherent,
displayed the spindle shape morphology (Fig. 1A) and typical cell
surface markers: positive for CD73, CD90, CD105, and HLA-I
and negative for CD34, CD45, CD14, CD31 and HLA-DR. The
percentage of cells expressing CXCR4 was>2% both in FLNA-
MSCs and in BM-MSCs. While the FLNA MSC proliferative
capacity, defined as cPD, was significantly higher (P<.00001)
than BM-MSC, (Fig. 1B).
The in vitro osteogenic and adipogenic differentiation assays
confirmed an osteogenic differentiation potential similar to BM-
MSCs and lack of adipogenic differentiation capacity (Fig. 1C).
Cells entered senescence phases at passage 14 (P14) (Fig. 1D).
Considering these characteristics we defined these in vitro
expanded cells from the patient’s pulmonary tissue as lung-MSCs.
4.10. Migration assay
Since the FLNA mutation may lead to a defect in cell motility, we
evaluated lung-MSC in vitro migration in comparison with BM-
MSC. The results of the transwell migration assay reported as the
Figure 1. Panel A: MSCs expanded from pulmonary tissue of the FLNA-defective pediatric patient exhibiting the typical spindle-shaped morphology. Magnification
4X; Panel B: cPD of FLNA-MSC and BM-MSC cultured to passage (P)5 (continuous line FLNA-MSC, broken line BM-MSC); Panel C: Adipogenic and osteogenic
differentiation capacity of BM-MSC and FLNA-MSCs. Differentiation into adipocytes, revealed by the formation of lipid droplets (stained with oil red O staining)
present in control BM-MSC resulted absent in FLNA-MSC. Differentiation into osteoblasts, demonstrated by the histological detection of AP activity (purple
reaction) and calcium deposition stained with Alzarin red staining, was similar in FLNA-MSC and BM-MSC. Magnification 10X; Panel D: b-gal staining of senescent
FLNA-MSC at P14 (stained in blue). BM-MSC=bone marrow-derived mesenchymal stem cells, cPD=cumulative population doubling, FLNA=filamin A, MSC=
mesenchymal stem cells.
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mean of the number of migrated cells per field, showed a
significantly reduced number (P= .026) in lung-MSC compared
with control BM-MSC (11.87±2.54 and 37±9.5, respectively),
Figure 2. No increases in cell migration were observed in wells
filled with SDF supplemented medium for either lung-MSCs or
control BM-MSC (9.0±1.5 and 21.5±5.3, respectively).
4.11. Genetic characterization
DNA sequencing analysis of pulmonary MSCs confirmed the
presence of the heterozygous frameshift variant,
NM_001110556.1:c.7391_7403del; (p.Val2464AlafsTer5), in
the FLNA gene, previously identified in the DNA from peripheral
blood of the same patient (Fig. 3).
5. Discussion
To the best of our knowledge, this is the first report on a gene
mutation in lung resident MSCs of an FLNA-defective patient.
This mutation may be responsible for defective MSC migration
and could have a causative role in the pulmonary damage
described in these patients.
FLNA is a protein that crosslinks actin filaments into
orthogonal networks in the cortical cytoplasm and participates
in the anchoring of membrane proteins to the actin cytoskeleton
establishing mechanical stability in cells.[1] Remodeling of the
cytoskeleton is central to the modulation of cell shape and
migration. The role of FLNA in cell migration is essential for
embryonic development. More precisely, FLNA localizes to
podosomes, which are cell structures involved in mesenchymal
migration via adhesion and matrix degradation properties.[15]
Adhesion and migration of cells into tissues, including tissue-
resident MSCs, are critical processes for organ formation,
homeostasis, and repair. The organism’s fitness is highly
dependent on the appropriate function of tissue stem cells.[16]
We demonstrated that MSCs isolated from FLNA-defective
pediatric lung tissue, according to the Mesenchymal and Tissue
Stem Cell Committee of the International Society for Cellular
Therapy Standards[17], are plastic adherent when cultured under
standard conditions, express the characteristic mesenchymal cell
surface antigens and have the capacity to differentiate into
osteoblasts; however, adipocyte differentiation capacity was not
detected. The differentiation tendencies of stem cells are closely
linked to several factors including adhesive context, mechanical
signals, and the physical responses of the cells.[18] Cytoskeletal
components composed of actin, microtubules, and intermediate
filaments in the cytoplasm play an important role in the elastic
properties of cells. These components vary in amount and
arrangement during stem cell differentiation, resulting in changes
in elasticity.[19–21] Therefore, due to the influence of FLNA on the
intrinsic mechanical properties of these cells, the role of an FLNA
mutation in defective MSC differentiation cannot be excluded.
MSCs from FLNA-defective pediatric lung tissue exhibited a
lower migration capacity compared to control BM-MSC. MSCs
express a number of chemokine receptors that are likely involved
in their migration capabilities,[22] possibly in combination with
growth factors and chemokines necessary for maximal effect.[23]
The contribution of the CXCL12 (SDF-1a)/CXCR4 axis to the
recruitment of bone marrow-derived stem cells in lung patholo-
gies has been demonstrated in a number of studies.[24–26] The
ability of MSCs to home and migrate appears to decrease during
in vitro expansion also in relation to their loss of surface
expression of chemokine receptors.[27–28] Moreover, the similar
CXCR4 expression inMSCs isolated from FLNA-defective tissue
compared with control BM-MSC suggests that the reduced
migration capability is probably not related to a chemokine/
receptor mechanism, but may be linked to an FLNA deficiency.
This alteration may be directly related to defects in cell migration
during embryonic lung development and in pulmonary damage
described in FLNA-defective patients.
The lung is a complex organ deriving from the endodermal and
mesodermal germ line. Normal lung development depends on the
well-orchestrated interaction between mesenchymal, epithelial,
and endothelial cells. Even though genetic and epigenetic
regulation, aswell as the specialized intra-, inter-, and extracellular
mechanisms responsible for proper development of the respiratory
system continue to be elucidated, each step in lung development is
reliant upon inductive cues and reciprocal interactions between the
pulmonary epithelium and the surrounding mesenchyme. Loss of
or abnormalities in cells and in their critical interactions can lead to
Figure 2. Representative immunofluorescence staining of BM-MSC and FLNA-MSC after 16hours of migration. A significantly reduced number of migrated cells
was evident for FLNA-MSCcomparedwith BM-MSC (blue=nuclei, scale bar=200mm). BM-MSC=bonemarrow-derivedmesenchymal stem cells, FLNA=filamin A.
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severe anatomical and functional defects in the airway and
alveoli.[29–32] MSC are key cells in the connective tissue hierarchy
of many organs, including the lung, and given the intimate
relationship between the epithelium and underlying mesenchyme
in the lung, both during branchingmorphogenesis and in the adult
it is likely that MSC play a crucial role in both the maintenance of
epithelial integrity and pathogenesis of lung disease.[31–32]
Even if a single case may represent a limit to the interpretation
of the results, in our FLNA-defective patient, dysfunctional lung
MSCs could have played a role in pathological lung development
causing neonatal emphysematous lesions. Subsequently, they
may limit repair, inducing dysfunctional matrix remodeling that
results in the development of progressive fibrotic lung disease.
Due to their tissue-regenerative and immunomodulatory
properties, MSCs have been proposed as cell therapy in lung
disease associated with dysregulated immune responses (e.g.,
chronic inflammation in chronic pulmonary disease) and
aberrant repair processes of lung tissue (e.g., idiopathic
pulmonary fibrosis (IPF). Results from preclinical studies using
MSCs to treat the genetic syndrome, cystic fibrosis, have been
reported.[33] The potential therapeutic role of healthy BM-MSC
cannot be excluded also in these defective patients.
In conclusion, we propose that dysfunctional FLNA-defective
MSCs have a role in pulmonary damage as described in FLNA-
defective patients. Further studies are mandatory to improve our
understanding of the role of MSCs in lung development and
disease in genetic disorders, in order to propose prospective cell
therapies.
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